Pulmatrix (PULM) EBITDA (2013 - 2026)

Pulmatrix has disclosed EBITDA across 14 years of filings, most recently posting -$1.0 million for Q2 2026.

• In Q2 2026, EBITDA rose 32.43% year-over-year to -$1.0 million; the TTM figure through Jun 2026 stood at -$4.1 million (up 48.63% YoY), while the FY2025 annual figure was -$5.2 million, up 47.06% from the prior year.
• EBITDA came in at -$1.0 million for Q2 2026 at Pulmatrix, up from -$1.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $747000.0 in Q1 2024 to a low of -$5.9 million in Q2 2024.
• Average EBITDA over 5 years is -$2.8 million, with a median of -$2.4 million recorded in 2023.
• Year-over-year, EBITDA soared 116.29% in 2024 and tumbled 347.26% in 2025.
• Over 5 years, EBITDA stood at -$4.3 million in 2022, then jumped by 48.55% to -$2.2 million in 2023, then increased by 12.27% to -$2.0 million in 2024, then surged by 53.48% to -$908000.0 in 2025, then retreated by 15.2% to -$1.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$1.0 million in Q2 2026, -$1.3 million in Q1 2026, and -$908000.0 in Q4 2025.